| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000 | Human,Mouse,Rat |
| Aliases | OPRD1; OPRD; Delta-type opioid receptor; D-OR-1; DOR-1 |
| Entrez GeneID | 4985; |
| WB Predicted band size | 36kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from human DOR-1 around the phosphorylation site of S363. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于DOR-1 (Phospho-Ser363)抗体的3篇模拟参考文献示例(注：内容为假设性概括，实际文献需通过数据库验证)：
---
1. **"Phosphorylation of Delta Opioid Receptor at Ser363 Modulates Agonist-Induced Internalization"**
*Author: Zhang L, et al.*
**摘要**: 本研究报道了DOR-1在Ser363位点的磷酸化对激动剂(如DPDPE)诱导受体内吞的关键作用，通过特异性Phospho-Ser363抗体证实该位点磷酸化与β-arrestin信号通路的关联。
2. **"Site-Specific Phosphorylation of Delta Opioid Receptor in Neuropathic Pain Models"**
*Author: Gupta R, et al.*
**摘要**: 利用Phospho-Ser363抗体检测神经损伤小鼠模型中DOR-1磷酸化水平的变化，发现Ser363磷酸化上调与镇痛耐受相关，提示其作为疼痛治疗的潜在靶点。
3. **"Development of a Phospho-Specific Antibody for Delta Opioid Receptor Ser363 and Its Application in GPCR Studies"**
*Author: Kim S, et al.*
**摘要**: 文章详细描述了Phospho-Ser363抗体的开发及验证流程，包括Western blot和免疫荧光实验，证明其在研究DOR-1激动剂依赖性磷酸化中的高特异性。
---
**建议**：实际文献需通过PubMed、Google Scholar等平台以关键词“DOR1 phosphorylation Ser363”或抗体货号(如厂商提供的)检索，并优先选择近5年内发表的或高引论文。
The DOR-1 (Phospho-Ser363) antibody is a specialized tool used to detect the delta-opioid receptor (DOR-1) when phosphorylated at serine residue 363. DOR-1. a G protein-coupled receptor (GPCR), is primarily expressed in the central nervous system and plays a critical role in pain modulation, emotional responses, and addiction pathways. Phosphorylation at Ser363 is a key post-translational modification associated with receptor desensitization and internalization, processes that regulate opioid receptor signaling and responsiveness to agonists like endogenous opioids or drugs. This modification is often mediated by GPCR kinases (GRKs) following receptor activation, contributing to downstream signaling attenuation or receptor trafficking.
The antibody is typically generated using synthetic peptides corresponding to the phosphorylated Ser363 epitope, ensuring specificity for the activated form of DOR-1. It is widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to study receptor dynamics in cellular or tissue samples. Researchers employ this tool to investigate mechanisms underlying opioid tolerance, dependence, and receptor recycling, particularly in models of chronic pain, substance use disorders, or neuropsychiatric conditions. Validation often includes testing in knockout models or phosphorylation-blocking assays to confirm target specificity. Its applications extend to preclinical studies aiming to develop therapies that modulate opioid receptor activity while minimizing adverse effects like addiction potential.
×
